News
Deep Analysis of Bo Lun
It has currently obtained the following honorary titles: Top 10 Chinese Pharmaceutical Outsourcing Companies, Top 10 Most Competitive Enterprises in China's Pharmaceutical Service Industry, National-level "Little Giant" Enterprise Specialized in Specialized, Refined, Differential and Innovative Fields, Guangdong Provincial-level Enterprise Technology Center, Guangdong Postdoctoral Innovation and Practice Base, Top 50 Most Investment-Worthy Enterprises in China, and Honorary Director Unit of the CRO Branch of China Pharmaceutical Quality Management Association (CPQMA).
Deep Analysis of Bo Lun
Deep Analysis of Bo Lun
2023-02-10
快讯！国家药监局发布《中药注册管理专门规定》
2022-11-14
快讯！CDE发布《双特异性抗体抗肿瘤药物临床研发技术指导原则》
2022-11-11
深析博论 | 如何与药审部门实现有效沟通？
2022-07-06
年中盘点|2022上半年共有29款新药获国家药监局批准
2022-05-18
深析博论 | 和黄、君实FDA审评再受挫，国药出海的问题究竟在哪？
2022-05-18
新型重磅降糖药获批，被称“天花板”，降糖没对手？
2022-05-16
CDE周报 | 承办55个临床试验申请，肿瘤药物占比第一，眼科药物占比第二
2022-05-09
CDE4月报 | 承办76个临床试验申请，肿瘤药物占比超过30%，呼吸道药物占比约15%
2022-04-25
CDE周报 | 承办26个临床试验申请，肿瘤药物占比超3成
2022-04-07